{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-005199","form_type":"8-K","ticker":"BCTX","cik":"0001610820","company_name":"BriaCell Therapeutics Corp.","filed_at":"2023-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.821755+00:00","generated_at":"2026-06-19T11:24:15.012402+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"BriaCell shareholders approve quorum amendment and elect directors at annual meeting","bullets":["Shareholders approved raising quorum to two holders representing at least 33 1/3% of outstanding shares.","All seven director nominees elected; votes ranged from 3.63M to 3.74M for each.","MNP LLP ratified as auditor with 6,651,809 votes for, none against, 11,560 abstain.","New omnibus equity incentive plan approved; 19,200 RSU grant to CEO ratified.","15,518,018 common shares outstanding; 6,663,370 shares represented at meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-005199","json":"https://secwatch.observer/filing/0001493152-23-005199.json","markdown":"https://secwatch.observer/filing/0001493152-23-005199.md","text":"https://secwatch.observer/filing/0001493152-23-005199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223005199/0001493152-23-005199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223005199/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T11:24:15.012402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ecaceed17efeb379917d482c147f480ce4005831","claim":"BriaCell Therapeutics Corp.: Amended Articles to raise quorum threshold for shareholder meetings to two shareholders holding at least 33 1/3% of outstanding shares (effective 2023-02-13).","evidence_excerpt":"On February13, 2023, BriaCell Therapeutics Corp. (the “Company”) amended its Articles to raise the quorum threshold for shareholder meetings to two shareholders who are, or who represent by proxy, shareholders who, in the aggregate, hold at least 33 1/3% of the outstanding shares entitled to be voted at the meeting.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223005199/0001493152-23-005199-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-02-13"}],"fact_type":"governance_change"},{"claim_id":"7a8174092541ae8a70101a959151c38eef738617","claim":"BriaCell Therapeutics Corp. shareholders approved Approve a new omnibus equity incentive plan. at the 2023-02-09 meeting.","evidence_excerpt":"Proposal 3. At the Meeting, the Company’s shareholders approved a new omnibus equity incentive plan (the “Omnibus Equity Incentive Plan”). The result of the votes to approve the Omnibus Equity Incentive Plan was as follows: For Against Abstain Broker Non-Votes 3,169,080 548,283 28,145 2,917,862","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223005199/0001493152-23-005199-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-02-09"}],"fact_type":"shareholder_vote"},{"claim_id":"8d397ef30b02029765e3200305c67b784d8cbd26","claim":"BriaCell Therapeutics Corp. shareholders approved Authorize and approve an amendment to the Articles to raise the quorum threshold for shareholder meetings to two shareholders holding at least 33 1/3% of outstanding shares. at the 2023-02-09 meeting.","evidence_excerpt":"Proposal 5. At the Meeting, the Company’s shareholders authorized and approved an amendment to the Articles of the Company to raise the quorum threshold for shareholder meetings to two shareholders who are, or who represent by proxy, shareholders who, in the aggregate, hold at least 33 1/3% of the outstanding shares entitled to be voted at the meeting (the “Quorum Amendment”). The result of the votes to approve the Quorum Amendment was as follows: For Against Abstain Broker Non-Votes 3,695,624 41,488 8,396 2,917,862","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223005199/0001493152-23-005199-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-02-09"}],"fact_type":"shareholder_vote"},{"claim_id":"d68abe5e7f66a55718eee4cd13006eae1f10c45a","claim":"BriaCell Therapeutics Corp. shareholders approved Election of seven nominees as directors. at the 2023-02-09 meeting.","evidence_excerpt":"Proposal 2. At the Meeting, the terms of seven (7) members of the Board expired. Each of the seven (7) nominees for director (the “Nominees”) were elected to serve until the next annual meeting of shareholders, or until his/her successor is duly elected or appointed, unless he/she resigns, is removed, or becomes disqualified in accordance with the Articles of the Company or the British Columbia Corporations Act. The result of the votes to elect the Nominees was as follows: Directors For Against Withheld Broker Non-Votes Dr. Jane Gross 3,695,837 0 49,672 2,917,861 Mr. Marc Lustig 3,651,900 0 93,608 2,917,862 Mr. Jamieson Bondarenko 3,742,891 0 2,618 2,917,861 Dr. William V. Williams 3,743,095 0 2,414 2,917,861 Dr. Rebecca Taub 3,740,940 0 4,569 2,917,861 Mr. Vaughn C. Embro-Pantalony 3,733,000 0 12,508 2,917,862 Mr. Martin Schmieg 3,739,718 0 5,791 2,917,861","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223005199/0001493152-23-005199-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-02-09"}],"fact_type":"shareholder_vote"},{"claim_id":"da58b20a5780c0093d86086f6fbfb806aa6e2cf3","claim":"BriaCell Therapeutics Corp. shareholders approved Ratify the appointment of MNP LLP as auditors for the Company and authorize the Board to fix auditors' remuneration and terms of engagement. at the 2023-02-09 meeting.","evidence_excerpt":"Proposal 1. At the Meeting, the shareholders ratified the appointment of MNP LLP as auditors for the Company and the authorization of the Board of Directors of the Company (the “Board”) to fix the auditors’ remuneration and terms of engagement. The result of the votes to ratify the appointment of MNP LLP was as follows: For Against Abstain Broker Non-Votes 6,651,809 0 11,560 1","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223005199/0001493152-23-005199-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-02-09"}],"fact_type":"shareholder_vote"},{"claim_id":"f36cb3f182eabf9cbb7934ce74cf657a75556336","claim":"BriaCell Therapeutics Corp. shareholders approved Ratify, confirm and approve a grant of 19,200 restricted share units under the Omnibus Equity Incentive Plan to the CEO on August 2, 2022. at the 2023-02-09 meeting.","evidence_excerpt":"Proposal 4. At the Meeting, upon approving the Omnibus Equity Incentive Plan, the Company’s shareholders ratified, confirmed and approved a grant of 19,200 restricted share units under the Omnibus Equity Incentive Plan to the Company’s Chief Executive Officer on August 2, 2022 (the “RSU Award”). The result of the votes to approve the RSU Award was as follows: For Against Abstain Broker Non-Votes 3,622,931 96,879 25,698 2,917,862","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223005199/0001493152-23-005199-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-02-09"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}